MedImmune

Sidney Mazel, Ph.D., has been named senior vice president, product planning and portfolio management, at MedImmune. In this newly created position, Dr. Mazel will lead the life-cycle management of the company’s expanding portfolio of products and product candidates. Specifically, he will be responsible for new product planning, project management, market research and competitive intelligence.

“Sid will be bridging between product development and commercialization to drive long-term strategic planning to maximize the value of our existing products and our products in development,” said David M. Mott, president and chief executive officer. “He brings tremendous capabilities in life-cycle management and strategic planning from both his experience in industry at Merck and Wyeth and from his background in consulting at Pittiglio, Rabin, Todd and McGrath.”

Prior to joining MedImmune, Dr. Mazel held a number of senior leadership positions at Merck, most recently holding the title of vice president of worldwide marketing planning for Merck’s obesity and atherosclerosis franchise. In this position, he had global responsibility for the division’s long-term business strategy, new product development, market and competitive intelligence, life-cycle strategies, licensing, labeling and opinion leader management. At Merck, he was also selected to lead a corporate-wide franchise life-cycle management project to ensure optimal strategic planning across all therapeutic areas.

Previously, Dr. Mazel was a principal with Pittiglio, Rabin, Todd and McGrath, a consulting firm that provides services to improve strategic planning, technology management, product development and marketing operations for leading pharmaceutical and biotechnology companies. Prior to his consulting work, Dr. Mazel held a number of increasingly responsible positions in the research and marketing departments at Wyeth Pharmaceuticals.